Conference Description:

Dedicated to Realizing the Commercial Potential of Gene Therapies

Now is a crucial time for the gene therapy field, as the ripple effects of the pioneering first US gene therapy approval are being felt globally, setting new benchmarks and posing unexpected questions.

Rather than early stage basic science, the Gene Therapy for Rare Disorders Europe Conference is solely devoted to addressing the latest clinical, manufacturing, regulatory and commercialization challenges facing this rapidly evolving field. This is a comprehensive guide to define your commercial path forward.

Here’s a snapshot of the companies who attended last year:

Pfizer – Shire – Lysogene – BioMarin – Novasep – Horama – Orchard Therapeutics – Avrobio – Genzyme – Astellas – uniQure – Syneos Health – REGENXBIO – Chiesi – TIGET – Syncona – GenSight – GSK – Covance – Bioverativ – Cell Therapy Catapult – Vertex – DAK Gesundheit – MHRA – Vivet – Oxford Genetics – Innovate UK – Gilead – IQVIA – Servier – Rocket Pharma

Join your colleagues and accelerate the progress of the next generation of gene therapies that show improved efficacy, enhanced safety and commercial viability.

Early booking and group discounts are available. Register early to ensure the best possible rate for you and your colleagues.

Tickets https://go.evvnt.com/244419-1? pid=154
Brochure https://go.evvnt.com/244419-3?pid=154

Prices:
Conference + Workshop (Register by Friday 13 July) GBP 2298.0
Conference Only (Register by Friday 13 July) GBP 1799.0
Conference + Workshop (Standard Price) GBP 2598.0
Conference Only (Standard Price) GBP 2099.0
Workshop Only (Standard Price) GBP 599.0

Speakers: Karen Aiach (Lysogene), Celine Bouquet (GenSight Biologics), Emily Culme-Seymour (GSK), Omar Dabbous (AveXis), Anne Douar (Vivet Therapeutics), Alan Griffith (MeiraGTx), Matthew Hankinson (Allergan), Sven Kili (GSK), Nerissa Kreher (Avrobio), Aurelie Lambert (BioMarin), Christine Le Bec (Genethon), Robert Morgan (Nightstar Therapeutics), Jan Nilsson (CombiGene), Detlev Parow (DAK-Gesundheit), Steven Pearson (ICER), Hanspeter Rottensteiner (Shire)

Time: on Monday October 22, 2018 at 8:30 am (ends Wednesday October 24, 2018 at 5:00 pm)